New eye drop could offer relief for dry eye sufferers unhappy with restasis
NCT ID NCT07267299
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether switching from Restasis to a new eye drop called acoltremon 0.003% can better relieve dry eye symptoms and improve tear production. About 100 adults with chronic dry eye who are dissatisfied with Restasis will take part. Researchers will measure changes in tear production and symptom scores over 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acoltremon 0.003% eye drops
What this could lead to
If successful, this could offer a more effective option for people with chronic dry eye who are not satisfied with Restasis.
What could go wrong
This is a small, early-phase trial with only 100 participants and a short 28-day follow-up. Results may not apply to all dry eye patients, and the improvement may be modest.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••